|1.||Celio, Luigi: 11 articles (01/2015 - 07/2008)|
|2.||Rojas, Camilo: 8 articles (12/2015 - 08/2008)|
|3.||Slusher, Barbara S: 7 articles (12/2015 - 01/2010)|
|4.||Cox, David: 7 articles (07/2014 - 08/2011)|
|5.||Trissel, Lawrence A: 7 articles (01/2009 - 10/2004)|
|6.||Navari, Rudolph M: 6 articles (01/2015 - 11/2007)|
|7.||Grunberg, Steven M: 5 articles (10/2015 - 12/2003)|
|8.||Gralla, Richard J: 5 articles (09/2015 - 04/2006)|
|9.||Aapro, Matti: 5 articles (01/2015 - 01/2004)|
|10.||Agustoni, Francesco: 5 articles (01/2015 - 03/2012)|
07/01/2014 - "In conclusion, palonosetron and first-generation 5-HT3 RAs were at least equally effective in emesis prophylaxis for allo-HSCT recipients. "
08/01/2014 - "However, palonosetron has also shown consistent improvement in the suppression of delayed emesis. "
02/01/2016 - "Patients' satisfaction, assessed using Functional Living Index-Emesis (FLI-E), GTDS cycle were higher than those of palonosetron cycle in GP group (FLI-E score; median 1549.5 in GTDS cycle, median 1670.0 in palonosetron cycle). "
08/01/2014 - "Results provide a possible explanation for palonosetron's enhancement of the inhibition of the SP response and suggest that the effect of palonosetron and NK1 receptor antagonists on prevention of delayed emesis could be additive. "
07/01/2014 - "Patients receiving palonosetron, especially for acute emesis, required rescue therapy less frequently than those receiving first-generation 5-HT3 RAs. "
02/01/2015 - "Along with a more complete response, the severity of nausea was also lesser with palonosetron during the corresponding study periods (2-24 and 24-48 h, respectively; p < 0.05). "
07/01/2014 - "Palonosetron may be more effective than older 5-HT3 RAs in preventing nausea, with comparable tolerability. "
07/01/2014 - "Numerically more palonosetron-treated patients were nausea-free on each day, and fewer had moderate-severe nausea. "
03/01/2014 - "The incidence of nausea was also significantly lower in the palonosetron group than in the placebo group during the 0-24 and 0-72 h period (P<0.05), but not during the 24-72 h postoperative period. "
01/01/2014 - "She was ultimately treated with palonosetron with complete resolution of her acute nausea. "
|3.||Postoperative Nausea and Vomiting (PONV)
02/01/2015 - "A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period."
10/01/2015 - "The data showed statistically significant differences in favor of palonosetron (0.075 mg) in the prevention of acute PONV (P < .00001) and delayed PONV (P < .002), reducing the risk of PONV by 49% and 51%, respectively. "
03/01/2014 - "Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial."
02/01/2015 - "We performed a multicenter, randomized, double-blind trial to assess the efficacy and safety of a single, fixed, intravenous dose of palonosetron (0.075 mg) in the treatment of established postoperative nausea and vomiting (PONV). "
08/01/2014 - "The purpose of this study was to determine whether continuous infusion of palonosetron following single injection could reduce PONV to a greater extent than single injection only of palonosetron. "
07/01/2012 - "The second-generation 5-HT(3) antagonist palonosetron is highly effective in preventing CINV in patients with solid tumors. "
10/01/2015 - "Combination therapy of palonosetron and 1-day DEX was effective for subjects undergoing a TC regimen for gynecologic cancers. "
10/01/2012 - "The purpose of this study is to determine acute effects of palonosetron on electrocardiographic (ECG) parameters in cancer patients. "
04/01/2011 - "The regression model predicted a 13.7% decrease in CINV event rate per CTH cycle for Group 1 versus Group 2. For Subgroup 1, the model predicted a 12.5% decrease in the CINV event rate per cycle in Group 1 patients versus those in Group 2. In this study, patients with cancer who were treated with CTH and on antiemetic prophylaxis using palonosetron were found to have significantly lower CINV event rates than those receiving other 5-HT(3) receptor antagonists."
01/01/2011 - "We identified randomized controlled clinical trials (RCT) comparing palonosetron with first-generation 5-HT3RA in the prevention of CINV in cancer patients. "
02/01/2014 - "No patients in the palonosetron group experienced severe pain. "
04/01/2013 - "Intrathecal and intraplantar palonosetron (0.5 µg) had no effect on modulating the mechanical hypersensitivity in the incisional pain model of rats."
01/01/2014 - "We evaluated the efficacy of palonosetron for reducing pain after rocuronium injection. "
04/01/2013 - "In this study, we evaluated the effects of palonosetron, a 5-HT3 receptor antagonist, on incisional pain in rats when administered intrathecally or intraplantarly. "
04/20/2014 - "Pain intensity scores were significantly lower in the ramosetron group than the palonosetron group for 72 hours postoperatively. "
|3.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|7.||Serotonin (5 Hydroxytryptamine)
|9.||Serotonin 5-HT3 Receptor Antagonists
|1.||Drug Therapy (Chemotherapy)
|2.||Patient-Controlled Analgesia (Analgesia, Patient Controlled)
|4.||Gynecologic Surgical Procedures (Gynecologic Surgery)